IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES
An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae , in particular against S. pneumoniae serogroup 10A and 39, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.
1 . An immunogenic composition comprising at least one glycoconjugate from Streptococcus pneumoniae serotype 10A and a carrier protein, wherein said immunogenic composition is able to elicit IgG antibodies in a human at a concentration of at least 0.35 ug/mL as determined by ELISA assay, and wherein said anti-IgG antibodies are able to bind S. pneumoniae serotype 39 polysaccharides.
2 . The immunogenic composition of claim 1 , further comprising glycoconjugates from S. pneumoniae serotypes 4, 6B, 14, 18C, 19F and 23F.
3 . The immunogenic composition of claim 2 , further comprising at least one glycoconjugate from S. pneumoniae serotype 1, 5 and 7F.
4 . The immunogenic composition of claim 3 , further comprising glycoconjugates from S. pneumoniae serotypes 3, 6A and 19A.
5 . The immunogenic composition of claim 3 , further comprising glycoconjugates from S. pneumoniae serotypes 22F and 33F.
6 . The immunogenic composition of claim 3 , further comprising glycoconjugates from S. pneumoniae serotypes 8, 11A, 12F, and 15B.
7 . The immunogenic composition of claim 1 which is a 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 or 26-valent pneumococcal conjugate composition.
8 . The immunogenic composition of claim 1 , wherein said immunogenic composition further comprises at least one adjuvant.
9 . The immunogenic composition of claim 1 which is able to elicit a titer of at least 1:8 against S. pneumoniae serotype 10A in at least 50% of the subjects as determined by in vitro opsonophagocytic killing assay (OPA).
10 . The immunogenic composition of claim 1 , wherein said carrier protein is selected from the group consisting of Diphtheria toxin (DT), tetanus toxoid (TT), CRM 197 , the A chain of diphtheria toxin mutant CRM 197 , CRM 176 , CRM 228 , CRM 4 S, CRM 9 , CRM 102 , CRM 103 , CRM 107 , and Haemophilus influenzae protein D (PD).